JOURNAL ARTICLE
Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.
Clinical and Experimental Dermatology 2010 January
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by abscess formation localized to apocrine sweat gland-bearing skin. The most important factor in patients' overall assessment of disease severity is pain. The duration of abscesses takes days to weeks and are always painful.
AIM: To assess the efficacy of self-treatment with topical 15% resorcinol in an open study.
METHODS: The case notes of 12 women with stage 1 or 2 HS treated with topical resorcinol and followed up for at least 1 year were reviewed. The patients rated the efficacy of treatment on global maximum pain of nodules and abscesses on a visual analogue scale (VAS) and by self-report of the mean duration (days) of a painful lesion.
RESULTS: All patients experienced a significant decrease in pain as assessed by VAS and reported a reduction in mean duration of the painful abscesses.
CONCLUSIONS: Topical treatment with 15% resorcinol reduced pain from painful nodules in all patients with HS. Further trials are warranted to confirm these results.
AIM: To assess the efficacy of self-treatment with topical 15% resorcinol in an open study.
METHODS: The case notes of 12 women with stage 1 or 2 HS treated with topical resorcinol and followed up for at least 1 year were reviewed. The patients rated the efficacy of treatment on global maximum pain of nodules and abscesses on a visual analogue scale (VAS) and by self-report of the mean duration (days) of a painful lesion.
RESULTS: All patients experienced a significant decrease in pain as assessed by VAS and reported a reduction in mean duration of the painful abscesses.
CONCLUSIONS: Topical treatment with 15% resorcinol reduced pain from painful nodules in all patients with HS. Further trials are warranted to confirm these results.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app